Faculty Collaboration Database

Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Surg Oncol Clin N Am 1998 Jan;7(1):183-97

Date

03/07/1998

Pubmed ID

9443995

DOI

10.1016/s1055-3207(18)30293-x

Scopus ID

2-s2.0-0031886329 (requires institutional sign-in at Scopus site)   20 Citations

Abstract

Pancreaticoduodenectomy is performed on carefully selected patients as part of a protocol-based clinical research program emphasizing the importance of multimodality management for patients with potentially resectable adenocarcinoma of the pancreatic head. Treatment schemas emphasize the importance of minimizing toxicity and treatment duration, while attempting to improve therapeutic efficacy. Cytotoxicity is enhanced by combining radiation therapy with more potent radiation-sensitizing agents. Because of the high incidence of liver metastases, systemic therapy is continued after chemoradiation and surgery with systemic agents of low toxicity directed at specific molecular events involved in pancreatic tumorigenesis such as inhibition of angiogenesis, induction of apoptosis, or arrest of the cell cycle.

Author List

Miller AR, Robinson EK, Lee JE, Pisters PW, Chiao PJ, Lenzi RL, Abbruzzese JL, Evans DB

Author

Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adenocarcinoma
Antineoplastic Agents
Chemotherapy, Adjuvant
Humans
Pancreatic Neoplasms
Pancreaticoduodenectomy
Radiation-Sensitizing Agents
Radiotherapy, Adjuvant